DB 1310
Alternative Names: DB-1310Latest Information Update: 17 Oct 2025
At a glance
- Originator Duality Biologics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 17 Oct 2025 Synnovation in collaboration with DualityBio plans to initiate a clinical trial (Combination therapy)
- 21 Jul 2025 DB 1310 receives Fast Track designation for Non-small cell lung cancer [IV] (In adults, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
- 05 Jun 2025 Preliminary efficacy and adverse event data from a phase I/IIa trial in Solid tumours released by Duality Biologics